Gilead Sciences new drug keeps 56 percent of lymphoma trial patients alive Ruby Khatun Khatun11 Dec 2017 5:00 AM GMTMore than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a...
Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales Ruby Khatun Khatun11 Nov 2017 4:00 AM GMTRegeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand...
Merck to stop development of hepatitis C treatments Ruby Khatun Khatun4 Oct 2017 4:50 AM GMTU.S. drugmaker Merck & Co said on Friday it would discontinue developing an experimental drug combination for chronic hepatitis C, as competition...